Skip to main content
Premium Trial:

Request an Annual Quote

Arcturus Adds Second ATTR Program to Pipeline

Premium

NEW YORK (GenomeWeb) – Arcturus Therapeutics has announced that it has added a second drug candidate to its transthyretin-mediated amyloidosis (ATTR) program.

ATTR disease is caused by mutations in the transthyretin (TTR) gene, which triggers the accumulation of abnormal amyloid proteins in the body. Previously, Arcturus announced that it is developing an ATTR drug designed to silence both the wild-type and mutant forms of the gene, which would be used for patients with a form of ATTR that primarily damages heart tissue called familial amyloidotic cardiomyopathy (FAC).

This week, the company announced new preclinical data showing that its RNAi molecules, which incorporate proprietary unlocked nucleobase analog modifications, are capable of silencing mutant TTR while leaving the wild-type form intact.

Based on these data, Arcturus has added a mutant allele-specific ATTR candidate to its drug-development roster. According to a company official, the new compound will be developed for another form of ATTR called familial amyloidotic polyneuropathy, or FAP, which is characterized by damage to the peripheral nervous system.

Arcturus has previously stated that its FAC drug is slated to enter the clinic in early 2015.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.